- Home
- SURG vs CUE Comparison
SURG vs CUE Comparison
Compare SURG & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SURG
- CUE
- Stock Information
- Founded
- SURG 2006
- CUE 2014
- Country
- SURG United States
- CUE United States
- Employees
- SURG N/A
- CUE N/A
- Industry
- SURG Advertising
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- SURG Consumer Discretionary
- CUE Health Care
- Exchange
- SURG Nasdaq
- CUE Nasdaq
- Market Cap
- SURG 56.1M
- CUE 59.5M
- IPO Year
- SURG N/A
- CUE 2018
- Fundamental
- Price
- SURG $2.76
- CUE $0.78
- Analyst Decision
- SURG Strong Buy
- CUE Strong Buy
- Analyst Count
- SURG 1
- CUE 2
- Target Price
- SURG $9.00
- CUE $3.00
- AVG Volume (30 Days)
- SURG 158.5K
- CUE 108.9K
- Earning Date
- SURG 08-13-2025
- CUE 08-12-2025
- Dividend Yield
- SURG N/A
- CUE N/A
- EPS Growth
- SURG N/A
- CUE N/A
- EPS
- SURG N/A
- CUE N/A
- Revenue
- SURG $36,461,935.00
- CUE $8,286,000.00
- Revenue This Year
- SURG $47.01
- CUE N/A
- Revenue Next Year
- SURG $128.15
- CUE $10.19
- P/E Ratio
- SURG N/A
- CUE N/A
- Revenue Growth
- SURG N/A
- CUE N/A
- 52 Week Low
- SURG $1.05
- CUE $0.45
- 52 Week High
- SURG $3.47
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- SURG 54.84
- CUE 44.82
- Support Level
- SURG $2.64
- CUE $0.77
- Resistance Level
- SURG $2.89
- CUE $0.89
- Average True Range (ATR)
- SURG 0.13
- CUE 0.04
- MACD
- SURG 0.05
- CUE -0.01
- Stochastic Oscillator
- SURG 81.48
- CUE 5.98
About SURG SurgePays Inc.
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.